Mitomycine Substipharm

Mitomycin, the active ingredient in Mitomycine Substipharm, is an alkylating antineoplastic agent presented as a sterile injectable for intra‑arterial, intravenous, or intravesical use. It is employed in the treatment of several solid tumours, including bladder, gastric, pancreatic, breast and lung cancers, in adult oncology patients.

GNH USA supplies Mitomycine Substipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from regulatory support and consistent product availability across multiple markets.

Mitomycin is used in chemotherapy regimens targeting solid tumours that rely on DNA cross‑linking mechanisms. - Bladder cancer: reduces tumour recurrence after transurethral resection. - Gastric cancer: used in combination protocols for advanced disease. - Pancreatic cancer: incorporated into multi‑agent regimens for metastatic cases. - Breast cancer: applied in selected cases resistant to standard therapies. - Lung cancer: employed as part of combination chemotherapy for non‑small cell carcinoma.

Mitomycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported. - Myelosuppression: decreased white blood cells, platelets, and red cells. - Fatigue: generalized tiredness during treatment. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hemorrhagic cystitis: bladder inflammation with bleeding. - Severe infection: due to profound neutropenia. - Renal impairment: reduced kidney function in susceptible patients. - Cardiotoxicity: rare cardiac dysfunction or arrhythmia.

When using Mitomycin, clinicians should observe several safety measures to minimize risk. - Baseline blood counts: obtain complete blood count before each cycle to monitor myelosuppression. - Renal function: assess serum creatinine and adjust dose in patients with impaired kidneys. - Pulmonary assessment: perform lung function tests if history of respiratory disease. - Concomitant nephrotoxic drugs: avoid or closely monitor agents that may worsen kidney injury. - Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and avoid breastfeeding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - Antimetabolites (e.g., methotrexate): combined use markedly increases myelosuppression. - High‑dose radiation therapy: synergistic toxicity to normal tissues. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): may exacerbate renal toxicity. - CYP450 inducers or inhibitors: can alter mitomycin activation pathways. - Anticoagulants (e.g., warfarin): increased bleeding risk due to mucosal damage.